{"id":1312,"date":"2023-09-04T14:03:00","date_gmt":"2023-09-04T14:03:00","guid":{"rendered":"https:\/\/d.ptpl.dev\/acarix\/acarix-receives-initial-order-from-the-emerging-east-african-market\/"},"modified":"2024-08-06T12:24:45","modified_gmt":"2024-08-06T12:24:45","slug":"acarix-receives-initial-order-from-the-emerging-east-african-market","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/acarix-receives-initial-order-from-the-emerging-east-african-market\/","title":{"rendered":"Acarix receives initial order from the emerging East African market"},"content":{"rendered":"
\n

Acarix, a leader in acoustic and AI-based cardiac diagnostics, partners with Maeva Health, led by Dr. Peter Svalander, CEO, to launch the CADScor System in Mauritius and further on the expansive East African market with a population exceeding 485 million. As a result of the partnership, Maeva has placed an initial order of several Acarix CADScor Systems for rapid diagnosis of cardiac patients directly at the point of care.<\/strong><\/p>\n<\/div>\n

\n

Eastern Africa, including nations in the Indian Ocean, incorporates regions with momentous health challenges. Mauritius has adopted a Health Sector Strategic Plan to reduce preventable and premature morbidity, mortality, and disability by addressing their risk factors, with extra focus on cardiovascular disease. Maeva Health provides access to a complete value chain of integrated health diagnostics for advanced health profiling in these key areas with the goal of improving health and quality of life.<\/p>\n

"Our patients seek us out for tailored health assessments and guidance to enhance their well-being and optimize their quality of life," commented Dr. Peter Svalander, CEO of Maeva Health. "Considering the high prevalence of cardiovascular disease in Mauritius, the integration of this pioneering Scandinavian technology into our toolbox empowers us to rule out significant coronary artery concerns efficiently and precisely during the initial diagnostic phase, aligning perfectly with Maeva Health's objectives."<\/p>\n

"Our main focus is the US market, but we also understand the needs of diverse global markets and patient demographics that can benefit from the CADScor System," commented Helen Ljungdahl Round, Acarix's President and CEO. "One of our strategic initiatives is to provide access to the CADScor System for various patient populations and healthcare systems to ensure equitable healthcare for those who require it. Through our partnership with Maeva Health, we're leveraging the CADScor System's innovation to address early cardiovascular disease assessment among populations in developing countries.\u201d<\/p>\n

About AVA and Maeva Health<\/strong><\/p>\n

AVA is an integrated group of companies specializing in medical devices, the health services sector, and several other activities.\u00a0The group is based in Mauritius and currently employs over 700 people. For more information, please visit www.avagroup.mu<\/a><\/p>\n

Maeva Health, member of AVA, offers men and women preventive health examinations with a focus on cardiovascular diseases, cancer and diabetes which are the most common causes of premature death in the world. Early detection is key to reducing suffering and excessive medical expenses. For more information, please visit www.maevahealth.mu<\/a><\/p>\n<\/div>\n

\n

For more information contact:<\/strong>
Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46\u00a0730 770283, email helen.round@acarix.com<\/a>\u00a0
Christian Lindholm, CFO, phone +46\u00a0705 118333, email christian.lindholm@acarix.com<\/a><\/p>\n<\/div>\n

\n

About Acarix<\/strong><\/p>\n\n\n\n
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of coronary artery disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor\u00aeSystem is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. The CADScor System has been used on more than 29,000 patients and is recommended as a first-line diagnostic aid as outlined in the clinical workflow developed in collaboration with the American College of Cardiology (ACC). Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 8 121 576 90, certifiedadviser@redeye.se<\/a>) is Certified Advisor of Acarix. For more information, please visit www.acarix.com<\/a>.\u00a0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n

Attachments<\/strong>
Acarix receives initial order from the emerging East African market<\/a><\/p>\n<\/div>\n